Rebecca McClure, M.D., FCAP

Pathologist, Health Sciences North
Scientist, Health Sciences North Research Institute
Associate Professor, Northern Ontario School of Medicine

Dr. McClure attended the University of Toronto where she received her B.Sc. in Biology in 1989, and her M.Sc. in Medical Biophysics in 1991.  She stayed in Toronto for her medical training, and received her MD degree in 1994. She then relocated to the Mayo Clinic in Rochester, Minnesota where she completed residencies in Anatomic and Clinical Pathology followed by fellowships in Surgical Pathology and Hematopathology. In 2002, she joined the staff at Mayo Clinic as a pathologist in the Department of Laboratory Medicine and Pathology, where she has practiced for over 10 years.  During her time at Mayo, Dr. McClure maintained a busy, international clinical pathology practice and was active in teaching medical students, residents, fellows and graduate students through the Mayo Medical School, where she was an associate professor. She also created and directed the clinic’s Molecular Hematology Laboratory, a job that included developing and implementing the current broad menu of clinical tests that this laboratory performs on specimens from all over the world.

Selected Affiliations

American Society of Clinical Pathology – Member
American Society of Hematology – Member
Association of Molecular Pathology – Member
European Association of Haematopathology/ Society of Hematopathology – Member

Research Interests

Dr. McClure’s main research interest is understanding the genetics underlying leukemias and lymphomas. She spent much of her time at Mayo Clinic in the area of translational research, which involves dealing with the difficult, practical issues of transferring basic research findings into orderable clinical tests. In her capacity as the director of a large molecular testing laboratory, she was an early adopter of high-throughput sequencing technology for clinical test development. This powerful, new technology is rapidly changing the way medicine is practiced, as it allows physicians to rapidly, and cost-effectively, obtain large amounts of genetic information that has not been available in the past. Because abnormal genetic processes are responsible for a wide variety of disorders including cancers, inherited disorders and infectious diseases, the new technology has many applications in both the clinical setting and in research laboratories studying the genetics of these diseases.

Current Funding

Northern Cancer Foundation
NOAMA
Hoffman La-Roche
Boehringer-Engelheim

Selected Publications

  • McClure RF, Heppelmann CJ, Paya CV.  Constitutive Fas ligand gene transcription in Sertoli cells is regulated by Sp1.  J Biol Chem 1999;274:7756-7762. 
  • McClure RF, Dewald GW, Hoyer JD, Hanson CA.  Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course.  Br J Haematol 1999; 106:445-454. 
  • McClure R, Mai M, Lasho T.  Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.  Leukemia 2006; 20:168-171. 
  • McClure RF, Kaur P, Pagel E, Ouillette PD, Holtegaard CE, Treptow CL, Kurtin PJ.  Validation of immunoglobulin gene rearrangement detection by PCR using commercially available BIOMED-2 primers.  Leukemia 2006;20:176-179. 
  • McClure R, Khoury J, Feldman A, Ketterling R.  Clonal relationship between precursor B-cell acute lymphoblastic leukemia and histiocytic sarcoma: A case report and discussion in the context of similar cases.  Leuk Res. 2010; 34:e71-73
  • Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A.  A phase-2 trial of low-dose pomalidomide in myelofibrosis.  Leukemia. 2011 Feb; 25(2):301-4.
  • Pardanani A, Chen D, Abelrahman RA, Reichard KK, Zblewski D, Wood AJ, McClure RF, Butterfield JH, Hanson CA, Tefferi A. Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis. Leukemia 2013;27:2091-2094.
  • McClure R, Mai, M. High-throughput Sequencing Using Ion Torrent Personal Genome Machine for Clinical Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia. Journal of Molecular Diagnostics 2015;17:145-154.
  • Reichard K, Chen D, Pardanani A, McClure R, Howard M, Kurtin P, Wood A, Ketterling R, King R, He R, Morice W, Hanson C. Morphologically occult systemic mastocytosis in bone marrow: Clinicopathologic features and an algorithmic approach to diagnosis. Am J of Clin Pathol 2015;144:493-502.  
  • Pundir S, Vu H, McClure R, Lee H. VR23: A Quinoline-Sulfonyl Hybrid Proteosome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification. Cancer Res 2015;75:4164-4175. 

Contact

Telephone: 705-523-7100 ext.3763
Fax: (705) 675-4780
rmcclure@hsnsudbury.ca